Genitourinary Cancers Clinical Trials & Research at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials:

Urothelial Cancer
Prostate Cancer
Renal Cell Cancer


Urothelial

Prevalence of PD-L1 Expression in Patients with Advanced Urothelial Carcinoma (PREVAIL)

Treatment agent: Rucaparib (PARPi)
PI: Manasa Vulchi, MD
Study Coordinator: Diego
Resources and Links: clinicaltrials.gov NCT No: NCT03788746


Tucatinib Plus Trastuzumab in Patients with HER2+ Colorectal Cancer

Treatment: Tucatinib + Trastuzumab
PI: Ian Anderson, MD
Study Coordinator: Kayla
Resources and Links: clinicaltrials.gov NCT No: NCT03043313


Prostate

A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON2)

Treatment agent: Rucaparib (PARPi)
PI: Thomas Stanton, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT02952534


A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)

Treatment agent: Rucaparib (PARPi)
PI: Thomas Stanton, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT02975934


Renal Cell

A Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Carcinoma

Treatment: Everolimus
PI: Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links: clinicaltrials.gov NCT No: NCT04195750

Our Providers

Our Locations